Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clopidogrel versus ticagrelor/prasugrel in elderly high-bleeding-risk ACS patients
NL-OMON21629Not yet recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of clopidogrel, ticagrelor and prasugrel in acute coronary syndrome (ACS), Non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina (2 arms), sponsored by St. Antonius Ziekenhuis. Primary endpoints: Any bleeding episode and Net clinical benefit. Planned start Jul 2013; status: not yet recruiting.
02
Drugs
clopidogrelticagrelorprasugrel
03
Conditions
acute coronary syndrome (ACS)Non-ST-segment elevation myocardial infarction (NSTEMI)unstable angina
Beyond the preview
Go deeper on NL-OMON21629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21629.